TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07224763: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)

Sponsor: United Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT07224763 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07224763 Rescue Dossier →